We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Penumbra, Inc. (PEN - Free Report) is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The stock has an Earnings ESP of +11.11% and sports a Zacks Rank of 1 at present. PEN beat earnings estimates in the last reported quarter. Penumbra has a four-quarter earnings surprise of 37.56%, on average. Penumbra’s stock has gained 51.4% in the past six months. A medical stock worth considering as it has the right combination of elements to post an earnings beat this quarter.
Axos Financial Inc. (AX - Free Report) is the holding company for BofI Federal Bank, which provides financing for single and multifamily residential properties, small-to-medium size businesses in target sectors and selected specialty finance receivables.The company came out with quarterly earnings beating the Zacks Consensus Estimate. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Axos Financial posted revenues for the quarter ended December 2022, also surpassing the Zacks Consensus Estimate. The company has also topped consensus revenue estimates four times over the last four quarters. The estimate revisions trend for Axos Financial is currently favorable. It has outperformed the market so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Top Stock Picks for Week of February 13, 2023
Penumbra, Inc. (PEN - Free Report) is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The stock has an Earnings ESP of +11.11% and sports a Zacks Rank of 1 at present. PEN beat earnings estimates in the last reported quarter. Penumbra has a four-quarter earnings surprise of 37.56%, on average. Penumbra’s stock has gained 51.4% in the past six months. A medical stock worth considering as it has the right combination of elements to post an earnings beat this quarter.
Axos Financial Inc. (AX - Free Report) is the holding company for BofI Federal Bank, which provides financing for single and multifamily residential properties, small-to-medium size businesses in target sectors and selected specialty finance receivables.The company came out with quarterly earnings beating the Zacks Consensus Estimate. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Axos Financial posted revenues for the quarter ended December 2022, also surpassing the Zacks Consensus Estimate. The company has also topped consensus revenue estimates four times over the last four quarters. The estimate revisions trend for Axos Financial is currently favorable. It has outperformed the market so far this year.